Ajith Sominanda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ajith Sominanda has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Anna Fogdell-Hahn
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
8 shared publications J Hillert
Karolinska Institute, Department of Clinical Neuroscience, Division of Neurology R54, Karolinska University Hospital Huddinge, Sweden
3 shared publicationsJan Hillert
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
3 shared publicationsKatharina Fink
Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
2 shared publicationsMalin Lundkvist
Department of Clinical Neuroscience, Karolinska Institutet, Sweden
2 shared publicationsA. I. M. Nilsson Remahl
Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 29 November 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (11) , e0278285
Validity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients
Routine use of the Disease Activity Score-28 (DAS28) to assess the disease activity in rheumatoid arthritis (RA) is limited due to its dependency on laboratory investigations and the complex calculations involved. In contrast, the clinical disease activity index (CDAI) is simple to calculate, which makes the "treat to target" strategy for the management of RA more practical. We aimed to assess the validity of CDAI compared to DAS28 in RA patients in Sri Lanka. A total of 103 newly diagnosed RA patients were recruited, and their disease activity was calculated using DAS 28 and CDAI during the first visit to the clinic (0 months) and re-assessed at 4 and 9 months of follow-up visits. The validity of the CDAI, compared to DAS 28, was evaluated. Patients had a female preponderance (6:1) and a short symptom duration (mean = 6.33 months). Internal consistency reliability of CDAI, as assessed by Cronbach’s α test, was 0.868. Convergent validity was assessed by correlation and Kappa statistics. Strong positive correlations were observed between CDAI and DAS 28 at the baseline (0 months), 4 and 9 months of evaluation (Spearman’s r = 0.935, 0.935, 0.910, respectively). Moderate-good inter-rater agreements between the DAS-28 and CDAI were observed (Weighted kappa of 0.660, 0.519, and 0.741 at 0, 4, and 9 months respectively). Discriminant validity, as assessed by ROC curves at 0, 4th, and 9th months of the evaluation, showed the area under the curve (AUC) of 0.958, 0.979, and 0.910, respectively. The suggested cut-off points for different CDAI disease activity categories according to ROC curves were ≤ 4 (Remission), > 4 to ≤ 6 (low), > 6 to ≤ 18 (moderate), > 18 (high). These findings indicate that the CDAI has good concordance with DAS 28 in assessing the disease activity in RA patients, in this study sample.
- 29 November 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (11) , e0278285
Open AccessValidity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients
Routine use of the Disease Activity Score-28 (DAS28) to assess the disease activity in rheumatoid arthritis (RA) is limited due to its dependency on laboratory investigations and the complex calculations involved. In contrast, the clinical disease activity index (CDAI) is simple to calculate, which makes the "treat to target" strategy for the management of RA more practical. We aimed to assess the validity of CDAI compared to DAS28 in RA patients in Sri Lanka. A total of 103 newly diagnosed RA patients were recruited, and their disease activity was calculated using DAS 28 and CDAI during the first visit to the clinic (0 months) and re-assessed at 4 and 9 months of follow-up visits. The validity of the CDAI, compared to DAS 28, was evaluated. Patients had a female preponderance (6:1) and a short symptom duration (mean = 6.33 months). Internal consistency reliability of CDAI, as assessed by Cronbach’s α test, was 0.868. Convergent validity was assessed by correlation and Kappa statistics. Strong positive correlations were observed between CDAI and DAS 28 at the baseline (0 months), 4 and 9 months of evaluation (Spearman’s r = 0.935, 0.935, 0.910, respectively). Moderate-good inter-rater agreements between the DAS-28 and CDAI were observed (Weighted kappa of 0.660, 0.519, and 0.741 at 0, 4, and 9 months respectively). Discriminant validity, as assessed by ROC curves at 0, 4th, and 9th months of the evaluation, showed the area under the curve (AUC) of 0.958, 0.979, and 0.910, respectively. The suggested cut-off points for different CDAI disease activity categories according to ROC curves were ≤ 4 (Remission), > 4 to ≤ 6 (low), > 6 to ≤ 18 (moderate), > 18 (high). These findings indicate that the CDAI has good concordance with DAS 28 in assessing the disease activity in RA patients, in this study sample.
- Open Access
- 28 February 2018
- Published by Wiley in Multiple Sclerosis International
- Vol. 2018, 1-10
Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
Multiple sclerosis (MS) is a heterogeneous disease which is poorly studied in Asia, where the disease is known to be rare with significant differences in clinical and radiological presentations and intrathecal antibody response. Therefore the objective of this study was to determine clinical presentation, radiological and neurophysiological characteristics, and oligoclonal band status in Sri Lankan MS patients, following careful exclusion of patients with neuromyelitis optica spectrum disorders and other conditions mimicking multiple sclerosis. Sixty-nine MS patients were recruited to the study adhering to McDonald 2010 criteria. Their clinical presentation, characteristics of central nervous system lesions in magnetic resonance imaging, visual evoked potential (VEP) results, oligoclonal bands (OCB), and AQP4 antibody status were studied. Of 69 MS patients, 54%, 6%, and 1% were relapsing remitting, secondary progressive, and primary progressive, respectively, and 39% were patients with clinically isolated syndrome. The commonest clinical presentations were cerebral motor followed by cerebral sensory and optic neuritis. Majority had typical periventricular and infratentorial lesions in MRI. Though not clinically apparent, bilateral delay of P100 wave latency was present in 52%. OCB positivity was 42% and AQP4 antibody was positive in only one patient. In conclusion, this group of Sri Lankan MS patients shares most of the clinical and radiological features of Caucasian MS patients. However, the OCB positivity is lower in this group, when compared to the Caucasian MS populations.
- 28 February 2018
- Published by Wiley in Multiple Sclerosis International
- Vol. 2018, 1-10
Open AccessMultiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
Multiple sclerosis (MS) is a heterogeneous disease which is poorly studied in Asia, where the disease is known to be rare with significant differences in clinical and radiological presentations and intrathecal antibody response. Therefore the objective of this study was to determine clinical presentation, radiological and neurophysiological characteristics, and oligoclonal band status in Sri Lankan MS patients, following careful exclusion of patients with neuromyelitis optica spectrum disorders and other conditions mimicking multiple sclerosis. Sixty-nine MS patients were recruited to the study adhering to McDonald 2010 criteria. Their clinical presentation, characteristics of central nervous system lesions in magnetic resonance imaging, visual evoked potential (VEP) results, oligoclonal bands (OCB), and AQP4 antibody status were studied. Of 69 MS patients, 54%, 6%, and 1% were relapsing remitting, secondary progressive, and primary progressive, respectively, and 39% were patients with clinically isolated syndrome. The commonest clinical presentations were cerebral motor followed by cerebral sensory and optic neuritis. Majority had typical periventricular and infratentorial lesions in MRI. Though not clinically apparent, bilateral delay of P100 wave latency was present in 52%. OCB positivity was 42% and AQP4 antibody was positive in only one patient. In conclusion, this group of Sri Lankan MS patients shares most of the clinical and radiological features of Caucasian MS patients. However, the OCB positivity is lower in this group, when compared to the Caucasian MS populations.
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Clinical Neurology
- Vol. 14 (3) , 339-344
Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka
Gamage SM, et al. J Clin Neurol. 2018 Jul;14(3):339-344. https://doi.org/10.3988/jcn.2018.14.3.339
- 1 January 2018
- Published by XMLink in Journal of Clinical Neurology
- Vol. 14 (3) , 339-344
Open AccessApplicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka
Gamage SM, et al. J Clin Neurol. 2018 Jul;14(3):339-344. https://doi.org/10.3988/jcn.2018.14.3.339
- 2 May 2012
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (12) , 1775-1781
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
Neutralizing antibodies (NAbs) against interferon beta (IFNβ) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFNβ during 2003–2004 was 32% in a cross-sectional analysis of routine data. The aim of this study was to investigate whether the seroprevalence of NAbs, the levels of NAb titres and the IFNβ preparations used for treatment of multiple sclerosis patients had changed in 2009–2010. This study included 1296 patients, analysed for NAbs with the myxovirus resistance protein A gene expression assay in 2009–2010. The seroprevalence of NAbs had decreased to 19% in 2009–2010, which is significantly lower compared with the previous study in 2003–2004 (pp<0.0001). NAb seroprevalence has decreased since NAb monitoring became clinical practice in 2003, especially for patients with high NAb titres. This might be due to the stricter monitoring of NAb titres that prompt NAb positive patients to stop treatment, to preferential use of less immunogenic drugs and to alteration of drug formulations.
- 2 May 2012
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (12) , 1775-1781
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
Neutralizing antibodies (NAbs) against interferon beta (IFNβ) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFNβ during 2003–2004 was 32% in a cross-sectional analysis of routine data. The aim of this study was to investigate whether the seroprevalence of NAbs, the levels of NAb titres and the IFNβ preparations used for treatment of multiple sclerosis patients had changed in 2009–2010. This study included 1296 patients, analysed for NAbs with the myxovirus resistance protein A gene expression assay in 2009–2010. The seroprevalence of NAbs had decreased to 19% in 2009–2010, which is significantly lower compared with the previous study in 2003–2004 (pp<0.0001). NAb seroprevalence has decreased since NAb monitoring became clinical practice in 2003, especially for patients with high NAb titres. This might be due to the stricter monitoring of NAb titres that prompt NAb positive patients to stop treatment, to preferential use of less immunogenic drugs and to alteration of drug formulations.
- 29 September 2010
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 124 (2) , 130-134
Interleukin-2 gene expression in different phases of episodic cluster headache - a pilot study
Steinberg A, Sjöstrand C, Sominanda A, Fogdell‐Hahn A, Nilsson Remahl AIM. Interleukin‐2 gene expression in different phases of episodic cluster headache – a pilot study.Acta Neurol Scand: 2011: 124: 130–134.© 2010 John Wiley & Sons A/S. Background – The pathophysiology of cluster headache (CH) is still largely unknown. Immunological mechanisms have been suggested to be of importance. Aim – This study aimed to investigate cytokine interleukin‐2 (IL‐2) as a possible marker of immune system involvement in the pathophysiology of CH. Methods – Eight episodic patients with CH and 16 healthy headache‐free control subjects matched for age and gender were studied. Venous blood samples were drawn from the patients with CH on three occasions; during active period between headache attacks, during an attack and in remission. Venous blood samples were drawn once from each control subject. We analysed IL‐2 gene expression, using quantitative real‐time polymerase chain reaction. Results – Patients with CH had significantly increased relative IL‐2 gene expression levels between headache attacks during active CH period (median 9.9 IL‐2 cDNA/glyceraldehyde‐3‐phosphate dehydrogenase cDNA; IQR 6.2–10.3) compared to during attacks (median 2.8; IQR 0.7–3.2, P = 0.012), remission (median 1.6; IQR 0.9–1.8, P = 0.017) and controls (median 0.9; IQR 0.6–1.9, P = 0.0001). Conclusion – The increment of IL‐2 found during the active CH period may support a role for this cytokine and subsequently for the immune system in the pathophysiology of CH. An expansion of this study to a broader group of cytokines and a larger patient cohort is warranted.
- 29 September 2010
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 124 (2) , 130-134
Interleukin-2 gene expression in different phases of episodic cluster headache - a pilot study
Steinberg A, Sjöstrand C, Sominanda A, Fogdell‐Hahn A, Nilsson Remahl AIM. Interleukin‐2 gene expression in different phases of episodic cluster headache – a pilot study.Acta Neurol Scand: 2011: 124: 130–134.© 2010 John Wiley & Sons A/S. Background – The pathophysiology of cluster headache (CH) is still largely unknown. Immunological mechanisms have been suggested to be of importance. Aim – This study aimed to investigate cytokine interleukin‐2 (IL‐2) as a possible marker of immune system involvement in the pathophysiology of CH. Methods – Eight episodic patients with CH and 16 healthy headache‐free control subjects matched for age and gender were studied. Venous blood samples were drawn from the patients with CH on three occasions; during active period between headache attacks, during an attack and in remission. Venous blood samples were drawn once from each control subject. We analysed IL‐2 gene expression, using quantitative real‐time polymerase chain reaction. Results – Patients with CH had significantly increased relative IL‐2 gene expression levels between headache attacks during active CH period (median 9.9 IL‐2 cDNA/glyceraldehyde‐3‐phosphate dehydrogenase cDNA; IQR 6.2–10.3) compared to during attacks (median 2.8; IQR 0.7–3.2, P = 0.012), remission (median 1.6; IQR 0.9–1.8, P = 0.017) and controls (median 0.9; IQR 0.6–1.9, P = 0.0001). Conclusion – The increment of IL‐2 found during the active CH period may support a role for this cytokine and subsequently for the immune system in the pathophysiology of CH. An expansion of this study to a broader group of cytokines and a larger patient cohort is warranted.
- Open Access
- 1 September 2010
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (9) , 1095-1101
Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta
Recombinant interferon beta represents a mainstay in the treatment of patients with relapsing-remitting multiple sclerosis (MS).1 However, a proportion of interferon beta–treated MS patients develop antibodies that bind to interferon beta, which are called binding antibodies (BAbs); a subset of these exhibit neutralizing capacities and are known as neutralizing antibodies (NAbs).2 One of the critical effects of NAbs is the loss of interferon beta bioactivity in vivo,3 translating into loss of clinical and paraclinical efficacy of the drug.4 High titers of NAbs are associated with a longer persistence of these antibodies and with a greater loss of interferon beta activity.5,6 Differences have been observed in the seroprevalence of NAbs and the immunogenicity between different commercial preparations.7 These have been attributed to distinctions in the structure of interferon beta, dose, route of application, and amount of impurities as potential immunogenic factors during the development of NAbs.8,9
- 1 September 2010
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 67 (9) , 1095-1101
Open AccessInhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon Beta
Recombinant interferon beta represents a mainstay in the treatment of patients with relapsing-remitting multiple sclerosis (MS).1 However, a proportion of interferon beta–treated MS patients develop antibodies that bind to interferon beta, which are called binding antibodies (BAbs); a subset of these exhibit neutralizing capacities and are known as neutralizing antibodies (NAbs).2 One of the critical effects of NAbs is the loss of interferon beta bioactivity in vivo,3 translating into loss of clinical and paraclinical efficacy of the drug.4 High titers of NAbs are associated with a longer persistence of these antibodies and with a greater loss of interferon beta activity.5,6 Differences have been observed in the seroprevalence of NAbs and the immunogenicity between different commercial preparations.7 These have been attributed to distinctions in the structure of interferon beta, dose, route of application, and amount of impurities as potential immunogenic factors during the development of NAbs.8,9
- 8 December 2008
- Published by Wiley in European Journal of Neurology
- Vol. 16 (1) , 21-26
Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent
Background and purpose: Neutralizing antibody (NAb) titres may vary over time and thereby some patients can either lose or regain therapeutic effect of interferon beta (IFNβ). We assessed NAb titres in a large sample of multiple sclerosis (MS) patients to identify the pattern of fluctuation during 1–3 years.Methods: Data from IFNβ‐treated MS patients who had been tested for NAbs twice (n = 822) were analysed. NAb titres were compared between the first and the second samples across the critical NAb level of 150 TRU/ml, which we have previously reported to correlate with loss of bioactivity.Results: Of patients with NAb titres high enough to indicate loss of bioactivity (>150 TRU/ml) in the first analysis 15% showed titres low enough to indicate a regained bioactivity. Conversely, 6% of those without detectable NAbs or NAb titres below the critical level of 150 TRU/ml had shifted to titres above this limit, indicating potential loss of bioactivity. Fluctuation did not differ between IFNβ preparation used, treatment duration or sampling interval.Conclusion: A first NAb test is prognostic for the NAb status during the coming 1–3 years. Choice of IFNβ preparation had no influence on the chance of reverting to lower levels once NAb titres are high.
- 8 December 2008
- Published by Wiley in European Journal of Neurology
- Vol. 16 (1) , 21-26
Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent
Background and purpose: Neutralizing antibody (NAb) titres may vary over time and thereby some patients can either lose or regain therapeutic effect of interferon beta (IFNβ). We assessed NAb titres in a large sample of multiple sclerosis (MS) patients to identify the pattern of fluctuation during 1–3 years.Methods: Data from IFNβ‐treated MS patients who had been tested for NAbs twice (n = 822) were analysed. NAb titres were compared between the first and the second samples across the critical NAb level of 150 TRU/ml, which we have previously reported to correlate with loss of bioactivity.Results: Of patients with NAb titres high enough to indicate loss of bioactivity (>150 TRU/ml) in the first analysis 15% showed titres low enough to indicate a regained bioactivity. Conversely, 6% of those without detectable NAbs or NAb titres below the critical level of 150 TRU/ml had shifted to titres above this limit, indicating potential loss of bioactivity. Fluctuation did not differ between IFNβ preparation used, treatment duration or sampling interval.Conclusion: A first NAb test is prognostic for the NAb status during the coming 1–3 years. Choice of IFNβ preparation had no influence on the chance of reverting to lower levels once NAb titres are high.
- 1 December 2008
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 36 (6) , 1418-1425
Impression of Clinical Worsening Fails to Predict Interferon-β Neutralizing Antibody Status
The development of neutralizing antibodies (NAbs) against interferon-β (IFNβ) reduces clinical efficacy and markers of bioactivity in patients with multiple sclerosis (MS), although it has also been shown that a poor response to IFNβ coincided with unexpectedly low NAb levels. To try and resolve this incoherency, this study investigated 2822 patients referred to a NAb testing facility. The reason for NAb testing was indicated for 2506 patients: routine testing (76%), worsening of disease (14%) and other reasons (10%). Overall, 31% of patients were NAb positive and 17% had titres high enough to obliterate IFNβ bioactivity. The frequency of NAbs was similar in patients in the routine testing group compared with the worsening group. Samples showing high titres failed to be associated with worsening of symptoms. The study failed to show low NAb levels in patients responding poorly to IFNβ. It is concluded that it is not possible to predict NAb status by clinical impression of treatment response. This is likely to be an effect of the partial efficacy of IFNβ. Thus routine testing for NAbs must be carried out in order to identify NAb status in patients with MS.
- 1 December 2008
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 36 (6) , 1418-1425
Impression of Clinical Worsening Fails to Predict Interferon-β Neutralizing Antibody Status
The development of neutralizing antibodies (NAbs) against interferon-β (IFNβ) reduces clinical efficacy and markers of bioactivity in patients with multiple sclerosis (MS), although it has also been shown that a poor response to IFNβ coincided with unexpectedly low NAb levels. To try and resolve this incoherency, this study investigated 2822 patients referred to a NAb testing facility. The reason for NAb testing was indicated for 2506 patients: routine testing (76%), worsening of disease (14%) and other reasons (10%). Overall, 31% of patients were NAb positive and 17% had titres high enough to obliterate IFNβ bioactivity. The frequency of NAbs was similar in patients in the routine testing group compared with the worsening group. Samples showing high titres failed to be associated with worsening of symptoms. The study failed to show low NAb levels in patients responding poorly to IFNβ. It is concluded that it is not possible to predict NAb status by clinical impression of treatment response. This is likely to be an effect of the partial efficacy of IFNβ. Thus routine testing for NAbs must be carried out in order to identify NAb status in patients with MS.
- Open Access
- 28 June 2008
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 59 (6) , 611
Anti-Inflammatory Liver X Receptors and Related Molecules in Multiple Sclerosis Patients from Sardinia and Sweden
- 28 June 2008
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 59 (6) , 611
Open AccessAnti-Inflammatory Liver X Receptors and Related Molecules in Multiple Sclerosis Patients from Sardinia and Sweden
- 1 January 2008
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 79 (1) , 57-62
In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
Background: Development of neutralising antibodies (NAbs) against recombinant interferon-β (IFNβ) is a significant clinical problem in the treatment of multiple sclerosis (MS). Several methods are available to assess NAbs, but there is a lack of consensus on how the different NAb titre levels interfere with the efficacy of the drug, especially in the individual patient. Methods: NAb titres were measured with an in vitro MxA induction assay and the in vivo IFNβ response was assessed by measuring MxA mRNA expression using real-time PCR. Results: We identified titre levels of NAbs at which the IFNβ biological activity was reduced or abrogated. Patients with NAb titres of up to 150 TRU/ml (ten times reduction units per ml) still had retained IFNβ bioactivity, whereas greatly reduced levels of IFNβ bioactivity were found in patients with NAbs of 150–600 TRU/ml. Titres above 600 TRU/ml were associated with loss of IFNβ bioactivity. Similar results were obtained when TRAIL mRNA was used as a marker of the in vivo response to IFNβ. Conclusion: There is a stepwise loss of IFNβ bioactivity with increasing NAb titres and it is possible to identify functionally critical NAb titre levels that are useful to support treatment decisions at the individual patient level.
- 1 January 2008
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 79 (1) , 57-62
In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
Background: Development of neutralising antibodies (NAbs) against recombinant interferon-β (IFNβ) is a significant clinical problem in the treatment of multiple sclerosis (MS). Several methods are available to assess NAbs, but there is a lack of consensus on how the different NAb titre levels interfere with the efficacy of the drug, especially in the individual patient. Methods: NAb titres were measured with an in vitro MxA induction assay and the in vivo IFNβ response was assessed by measuring MxA mRNA expression using real-time PCR. Results: We identified titre levels of NAbs at which the IFNβ biological activity was reduced or abrogated. Patients with NAb titres of up to 150 TRU/ml (ten times reduction units per ml) still had retained IFNβ bioactivity, whereas greatly reduced levels of IFNβ bioactivity were found in patients with NAbs of 150–600 TRU/ml. Titres above 600 TRU/ml were associated with loss of IFNβ bioactivity. Similar results were obtained when TRAIL mRNA was used as a marker of the in vivo response to IFNβ. Conclusion: There is a stepwise loss of IFNβ bioactivity with increasing NAb titres and it is possible to identify functionally critical NAb titre levels that are useful to support treatment decisions at the individual patient level.